{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:33:44Z","timestamp":1789122824515,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.josat.2023.209151","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T12:56:00Z","timestamp":1693313760000},"page":"209151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Evaluation of urine drug screen falsification of results among patients with opioid use disorder receiving treatment in a telehealth model of care"],"prefix":"10.1016","volume":"154","author":[{"given":"Rebekah","family":"Rollston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott G.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winifred","family":"Gallogly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apryl D.","family":"Brandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Clear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2023.209151_bb0005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jsat.2017.10.002","article-title":"High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio","volume":"83","author":"Accurso","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2023.209151_bb0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42531","article-title":"Use of telemedicine for buprenorphine inductions in patients with commercial insurance or medicare advantage","volume":"5","author":"Barsky","year":"2022","journal-title":"JAMA Network Open"},{"issue":"10","key":"10.1016\/j.josat.2023.209151_bb0015","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/10408444.2018.1553935","article-title":"Definitive urine drug testing in office-based opioid treatment: A literature review","volume":"48","author":"Barthwell","year":"2018","journal-title":"Critical Reviews in Toxicology"},{"key":"10.1016\/j.josat.2023.209151_bb0020","article-title":"Feasibility, acceptability, and preliminary efficacy of a smartphone-based contingency management intervention for buprenorphine adherence","author":"DeFulio","year":"2022","journal-title":"Behavior Analysis in Practice"},{"issue":"9","key":"10.1016\/j.josat.2023.209151_bb0025","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1111\/add.15394","article-title":"Effectiveness of incentivised adherence and abstinence monitoring in buprenorphine maintenance: A pragmatic, randomised controlled trial","volume":"116","author":"Elarabi","year":"2021","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.josat.2023.209151_bb0030","doi-asserted-by":"crossref","first-page":"146","DOI":"10.17161\/kjm.v12i4.13263","article-title":"Synthetic urines in a buprenorphine clinic","volume":"12","author":"Embers","year":"2019","journal-title":"Kansas Journal of Medicine"},{"key":"10.1016\/j.josat.2023.209151_bb0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/bs.acc.2016.05.003","article-title":"Adulterants in urine drug testing","volume":"76","author":"Fu","year":"2016","journal-title":"Advances in Clinical Chemistry"},{"key":"10.1016\/j.josat.2023.209151_bb0040","article-title":"Buprenorphine dosage and urine quantitative buprenorphine, norbuprenorphine, and creatinine levels in an office-based opioid treatment program","volume":"15","author":"Furo","year":"2021","journal-title":"Substance Abuse: Research and Treatment"},{"key":"10.1016\/j.josat.2023.209151_bb0045","unstructured":"Genotox Laboratories. (n.d.). ToxDirect\u2122 Urine Drug Testing Retrieved January 31, 2023, from https:\/\/www.toxdirecttesting.com."},{"issue":"4","key":"10.1016\/j.josat.2023.209151_bb0050","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/ADM.0000000000000608","article-title":"Acceptability and feasibility of a mobile health application for video directly observed therapy of buprenorphine for opioid use disorders in an office-based setting","volume":"14","author":"Godersky","year":"2020","journal-title":"Journal of Addiction Medicine"},{"issue":"7","key":"10.1016\/j.josat.2023.209151_bb0055","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jat\/32.7.516","article-title":"Urinary buprenorphine concentrations in patients treated with suboxone as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay","volume":"32","author":"Hull","year":"2008","journal-title":"Journal of Analytical Toxicology"},{"issue":"1","key":"10.1016\/j.josat.2023.209151_bb0060","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11606-021-07174-w","article-title":"Initiating opioid use disorder medication via telemedicine during COVID-19: Implications for proposed reforms to the Ryan Haight act","volume":"37","author":"Huskamp","year":"2022","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.josat.2023.209151_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dadr.2022.100045","article-title":"Assessing the feasibility, usability and acceptability of the MySafeRx platform among individuals in outpatient buprenorphine treatment: Lessons learned from a pilot randomized controlled trial","volume":"3","author":"Janzow","year":"2022","journal-title":"Drug and Alcohol Dependence Reports"},{"issue":"3","key":"10.1016\/j.josat.2023.209151_bb0070","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/ADM.0000000000000323","article-title":"Appropriate use of drug testing in clinical addiction medicine","volume":"11","author":"Jarvis","year":"2017","journal-title":"Journal of Addiction Medicine"},{"issue":"10","key":"10.1016\/j.josat.2023.209151_bb0075","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamapsychiatry.2022.2284","article-title":"Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among medicare beneficiaries before and during the COVID-19 pandemic","volume":"79","author":"Jones","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.1016\/j.josat.2023.209151_bb0080","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/10408363.2020.1774493","article-title":"What the lab can and cannot do: Clinical interpretation of drug testing results","volume":"57","author":"Kapur","year":"2020","journal-title":"Critical Reviews in Clinical Laboratory Sciences"},{"issue":"7","key":"10.1016\/j.josat.2023.209151_bb0085","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/pme.12663","article-title":"Urine spiking in a pain medicine clinic: An attempt to simulate adherence","volume":"16","author":"Lee","year":"2015","journal-title":"Pain Medicine (Malden, Mass.)"},{"key":"10.1016\/j.josat.2023.209151_bb0090","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.drugalcdep.2018.01.015","article-title":"Perceptions and practices addressing diversion among US buprenorphine prescribers","volume":"186","author":"Lin","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"9","key":"10.1016\/j.josat.2023.209151_bb0095","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11920-022-01346-z","article-title":"Telehealth-based delivery of medication-assisted treatment for opioid use disorder: A critical review of recent developments","volume":"24","author":"Mahmoud","year":"2022","journal-title":"Current Psychiatry Reports"},{"issue":"1","key":"10.1016\/j.josat.2023.209151_bb0100","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4065\/83.1.66","article-title":"Urine drug screening: Practical guide for clinicians","volume":"83","author":"Moeller","year":"2008","journal-title":"Mayo Clinic Proceedings"},{"issue":"4","key":"10.1016\/j.josat.2023.209151_bb0105","first-page":"38","article-title":"A practical guide to urine drug monitoring","volume":"35","author":"Raouf","year":"2018","journal-title":"Federal Practitioner"},{"issue":"2","key":"10.1016\/j.josat.2023.209151_bb0110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/bmjinnov-2021-000816","article-title":"Collaborative, patient-centered care model that provides tech-enabled treatment of opioid use disorder via telehealth","volume":"8","author":"Rollston","year":"2022","journal-title":"BMJ Innovations"},{"issue":"6","key":"10.1016\/j.josat.2023.209151_bb0115","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/ADM.0000000000001006","article-title":"Perspectives of patients receiving telemedicine services for opioid use disorder treatment: A qualitative analysis of user experiences","volume":"16","author":"Sousa","year":"2022","journal-title":"Journal of Addiction Medicine"},{"issue":"4","key":"10.1016\/j.josat.2023.209151_bb0120","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1080\/08897077.2017.1356796","article-title":"Quantitative testing of buprenorphine and norbuprenorphine to identify urine sample spiking during office-based opioid treatment","volume":"38","author":"Suzuki","year":"2017","journal-title":"Substance Abuse"},{"key":"10.1016\/j.josat.2023.209151_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108917","article-title":"Video directly observed therapy for patients receiving office-based buprenorphine - A pilot randomized controlled trial","volume":"227","author":"Tsui","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.josat.2023.209151_bb0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/10550887.2011.642757","article-title":"The emerging buprenorphine epidemic in the United States","volume":"31","author":"Wish","year":"2012","journal-title":"Journal of Addictive Diseases"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923002023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923002023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:50:56Z","timestamp":1757433056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875923002023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":26,"alternative-id":["S2949875923002023"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2023.209151","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of urine drug screen falsification of results among patients with opioid use disorder receiving treatment in a telehealth model of care","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2023.209151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"209151"}}